PTJ
BEAM icon

Paul Tudor Jones’s Beam Therapeutics BEAM Stock Holding History

Paul Tudor Jones’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-22,100
Closed -$536K – 3500
2025
Q3 		$536K Buy
+22,100
New +$440K ﹤0.01% 2657

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Paul Tudor Jones's BEAM Position: Q2 2026 in Review

Paul Tudor Jones increased its Beam Therapeutics (BEAM) stake by 3.8% in Q2 2026, buying an estimated $53.8K and bringing the position to 49,092 shares worth $1.68M. The position accounts for ﹤0.01% of the portfolio, ranked #2062.

Paul Tudor Jones first reported a position in BEAM in Q2 2021 and has held it in 13 quarters since. The position peaked at $4.09M in Q3 2021. 275 funds tracked by Wall St. Rank hold BEAM as of Q2 2026.

  • Paul Tudor Jones held 49,092 shares of Beam Therapeutics worth $1.68M as of Q2 2026.
  • Paul Tudor Jones bought 1,782 Beam Therapeutics shares in Q2 2026, an estimated $53.8K.
  • Beam Therapeutics made up ﹤0.01% of Paul Tudor Jones's portfolio in Q2 2026, its #2062 holding.
  • Paul Tudor Jones first reported a position in Beam Therapeutics in Q2 2021 and has held it in 13 quarters since.
  • Paul Tudor Jones's Beam Therapeutics position peaked at $4.09M in Q3 2021.
  • 275 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2026.

Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.